BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel ...

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel ...

Results from a preclinical study in mice, led by EPFL, and a collaborative clinical study in patients show that the type 2 immune response – associated with parasitic infection and thought to play a ...

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic ...

ASP-2138 is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip ...

Results from a preclinical study in mice and a collaborative clinical study in patients show that the type 2 immune response -- associated with parasitic infection and thought to play a negative role ...

Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral ...

INBRAIN Cortical BCI; Image credit: INBRAIN Neuroelectronics This milestone represents a significant advancement in demonstrating the ability of graphene-based BCI technology beyond decoding and ...

including the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and ...

Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a ...